AU2021269832B2 - Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies - Google Patents

Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies Download PDF

Info

Publication number
AU2021269832B2
AU2021269832B2 AU2021269832A AU2021269832A AU2021269832B2 AU 2021269832 B2 AU2021269832 B2 AU 2021269832B2 AU 2021269832 A AU2021269832 A AU 2021269832A AU 2021269832 A AU2021269832 A AU 2021269832A AU 2021269832 B2 AU2021269832 B2 AU 2021269832B2
Authority
AU
Australia
Prior art keywords
antibody
antigen
binding fragment
ctla
tremelimumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021269832A
Other languages
English (en)
Other versions
AU2021269832A1 (en
Inventor
Shao-Chun Chang
John KURLAND
Alejandra NEGRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2021269832A1 publication Critical patent/AU2021269832A1/en
Priority to AU2024202963A priority Critical patent/AU2024202963B2/en
Application granted granted Critical
Publication of AU2021269832B2 publication Critical patent/AU2021269832B2/en
Priority to AU2024266949A priority patent/AU2024266949A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2021269832A 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies Active AU2021269832B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024202963A AU2024202963B2 (en) 2020-05-12 2024-05-03 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
AU2024266949A AU2024266949A1 (en) 2020-05-12 2024-11-28 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
US63/023,554 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2024202963A Division AU2024202963B2 (en) 2020-05-12 2024-05-03 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
AU2024266949A Division AU2024266949A1 (en) 2020-05-12 2024-11-28 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Publications (2)

Publication Number Publication Date
AU2021269832A1 AU2021269832A1 (en) 2022-05-19
AU2021269832B2 true AU2021269832B2 (en) 2024-09-19

Family

ID=75977756

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2021269832A Active AU2021269832B2 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
AU2024202963A Active AU2024202963B2 (en) 2020-05-12 2024-05-03 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
AU2024266949A Pending AU2024266949A1 (en) 2020-05-12 2024-11-28 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2024202963A Active AU2024202963B2 (en) 2020-05-12 2024-05-03 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
AU2024266949A Pending AU2024266949A1 (en) 2020-05-12 2024-11-28 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Country Status (12)

Country Link
US (3) US20220363762A1 (enExample)
EP (1) EP4021940A1 (enExample)
JP (2) JP7387912B2 (enExample)
KR (1) KR20230009354A (enExample)
CN (1) CN114729054A (enExample)
AU (3) AU2021269832B2 (enExample)
BR (1) BR112022021893A2 (enExample)
CA (1) CA3158607A1 (enExample)
IL (2) IL311936A (enExample)
MX (1) MX2022006728A (enExample)
TW (2) TW202535468A (enExample)
WO (1) WO2021228978A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054897A1 (en) * 2022-09-07 2024-03-14 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180079814A1 (en) * 2015-04-01 2018-03-22 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
WO2018064013A1 (en) * 2016-09-27 2018-04-05 Peregrine Pharmaceuticals, Inc. METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
AU2003221888B2 (en) 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
US11214620B2 (en) * 2016-06-20 2022-01-04 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
WO2018187227A1 (en) * 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
KR102693361B1 (ko) * 2017-05-26 2024-08-09 브루인 바이오사이언시스, 인크. 화학색전제
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
WO2019241742A1 (en) * 2018-06-14 2019-12-19 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
CA3102334A1 (en) * 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180079814A1 (en) * 2015-04-01 2018-03-22 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
WO2018064013A1 (en) * 2016-09-27 2018-04-05 Peregrine Pharmaceuticals, Inc. METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) - Full Text View - ClinicalTrials.gov" *
"Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC - Full Text View - ClinicalTrials.gov", 26 April 2017 (2017-04-26), pages 1 - 10, XP055832793 *
ANTONIA SCOTT ET AL: "Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 3 *

Also Published As

Publication number Publication date
JP2024016209A (ja) 2024-02-06
CA3158607A1 (en) 2021-11-18
AU2024202963A1 (en) 2024-05-30
BR112022021893A2 (pt) 2022-12-20
KR20230009354A (ko) 2023-01-17
EP4021940A1 (en) 2022-07-06
US20210355224A1 (en) 2021-11-18
AU2024266949A1 (en) 2024-12-19
CN114729054A (zh) 2022-07-08
AU2024202963B2 (en) 2025-11-20
WO2021228978A1 (en) 2021-11-18
JP7387912B2 (ja) 2023-11-28
JP2023524359A (ja) 2023-06-12
TWI870592B (zh) 2025-01-21
IL297640A (en) 2022-12-01
US20220363762A1 (en) 2022-11-17
TW202535468A (zh) 2025-09-16
TW202207976A (zh) 2022-03-01
MX2022006728A (es) 2022-06-09
US20240239893A1 (en) 2024-07-18
IL311936A (en) 2024-06-01
AU2021269832A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
JP6499971B2 (ja) 抗ｃｄ３８抗体及びレナリドマイドを含む組成物
CN110536905B (zh) 用于治疗肺癌的抗pd-1抗体
TW201808330A (zh) 藉由投予ｐｄ－１抑制劑治療皮膚癌之方法
AU2024202963B2 (en) Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
CN114746117B (zh) 抗dll3药剂的给药方案
EP4512421A1 (en) Drug combination of anti-tim-3 antibody and anti-pd-1 antibody
WO2021155840A1 (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
AU2023336562A1 (en) Compositions and methods for treating advanced solid tumors
CN118593700A (zh) 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法
EA050171B1 (ru) Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек
WO2023230554A1 (en) Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2025087358A1 (zh) 抗体药物偶联物用于治疗癌症的方法
WO2025167716A1 (zh) 抗间皮素抗体药物偶联物治疗癌症的方法
WO2025002263A1 (zh) 治疗组合及其用途和治疗方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)